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Oestrogen receptor-binding fragment associated gene 9, EBAG9, is an oestrogen-responsive gene that was identified in MCF-7
human breast carcinoma cell line. It is identical to RCAS 1, a cancer cell surface antigen possibly involved in immune escape. In the
present study, we examined the expression of EBAG9/RCAS1 in human epithelial ovarian cancer using immunohistochemistry,
immunoblotting and reverse transcription–polymerase chain reaction (RT–PCR). A total of 90 epithelial ovarian cancer cases were
examined immunohistochemically by means of the antibodies for EBAG9 and ERa. The correlation between EBAG9
immunoreactivity and clinicopathological parameters was examined. mRNA expression of EBAG9 and ERa were evaluated by
RT–PCR in 22 cases. The expression for EBAG9 and ERa was examined by immunoblotting in 12 ovarian cancer cell lines. EBAG9
immunoreactivity was detected in the surface and cytoplasm of carcinoma cells in 46 out of 90 cases (51.1%). EBAG9 expression was
significantly higher in serous histology (P¼0.0402) and advanced disease (P¼0.0206). No significant relationship was detected
between EBAG9 immunoreactivity and overall survival (P¼0.689). There was a highly significant correlation between EBAG9 and ER
immunoreactivity (Po0.0001). The EBAG9 mRNA was detected in 20 out of 22 cases. In all of the cases that were positive for ERa
mRNA, they were also positive for EBAG9 mRNA. Immunoreactive band corresponding to EBAG9 was detected in 11 out of 12 of
ovarian cancer cell lines, and was consistent with ERa expression. In conclusion, the wide distribution of EBAG9 and its relation to
advanced disease suggest that this protein may play important roles in epithelial ovarian cancer.
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Epithelial ovarian cancer is the leading cause of death from
gynaecological malignancies in the great majority of developed
countries (Akahira J et al, 2001; Akahira JI et al, 2001,). Sex steroid
hormones have been implicated in the aetiology and/or progres-
sion of some epithelial ovarian cancers. Both oestrogen (ER) and
progesterone receptors (PR) have been reported in human
epithelial ovarian cancer (Rao and Slotman, 1991; Akahira et al,
2002). In endometrial and breast carcinomas, steroid hormone
receptor status correlates well with response to hormonal
manipulation and prognosis (McGuire, 1978; Benraad et al, 1980;
Ehrlich et al, 1981; Kaupilla, 1984). However, in epithelial ovarian
carcinoma, the prognostic significance of tumour ER status among
patients still remains controversial (Bizzi et al, 1988; Masood et al,
1989; Sevelda et al, 1990; Rao and Slotman, 1991; Hempling et al,
1998).
Recently, oestrogen receptor-binding fragment associated gene 9
(EBAG9) has been identified as an oestrogen-responsive gene from
a cDNA library of MCF-7 human breast cancer cell line (Watanabe
et al, 1998). Oestrogen receptor-binding fragment associated gene
9 is identical to the receptor-binding cancer antigen expressed in
SiSo cells (RCAS1) (Nakashima et al, 1999). The EBAG9/RCAS1 is
a membrane molecule that acts as a ligand for a putative receptor
present in cells (Nakashima et al, 1999). In vitro studies have also
demonstrated that EBAG9/RCAS1 inhibits growth of activated
CD3
þ T lymphocytes, suggesting a possible involvement in the
immune escape of neoplastic cells (Nakashima et al, 1999).
Endocrine-immune interactions are considered to play an
important role in the development and/or progression of various
hormone-dependent neoplasms, but the details of these interac-
tions remain unclear.
Oestrogen receptor-binding fragment associated gene 9 is
demonstrated to be widely distributed in human breast
carcinoma, and may play an important role in the development
of this oestrogen-dependent cancer (Suzuki et al, 2001). Others
reported that RCAS1 is associated with poor prognosis and/or
advanced stage in various human cancers (Sonoda et al, 1996;
Kaku et al, 1999; Izumi et al (2001); Nakakubo et al, 2002).
However, the expression of EBAG9 and its clinical significance
have not been examined in epithelial ovarian cancer. Therefore,
in this study, we examined the expression of EBAG9 in
human epithelial ovarian cancer using immunohistochemistry,
reverse transcription–polymerase chain reaction (RT–PCR) and
immunoblotting. We also evaluated the correlations of EBAG9
immunoreactivity with various clinicopathological parameters
and ER status. Revised 4 February 2004; accepted 3 March 2004
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yMATERIALS AND METHODS
We studied a total of 90 cases of common epithelial ovarian
carcinoma. Information regarding age, performance status on
admission, histology, stage, grade, residual tumour after primary
surgery and overall survival was retrieved from the review of
patient charts. The median follow-up time of the patients in this
study was 54 months (18–112 months). Of 90 patients, 76 (84.4%)
received platinum-containing chemotherapy after operation.
Performance status was defined according to WHO criteria (World
Health Organization, 1979). Histology, stage and grade were
determined according to FIGO (International Federation of
Gynecology and Obstetrics) criteria (Shimizu et al, 1998). Residual
disease was determined by the amount of unresectable tumour left
following primary cytoreductive surgery. Optimal cytoreduction
was defined as no gross residual tumour greater than 2cm in
diameter, whereas suboptimal cytoreduction was defined as any
gross residual disease remaining greater than 2cm in diameter.
Overall survival was calculated from the time of initial surgery to
death, or the date of last contact. Survival times of patients still
alive or lost to follow-up were censored in December 2002. All of
these archival specimens were retrieved from the surgical
pathology files at Tohoku University Hospital, Sendai, Japan.
These specimens were all fixed in 10% formalin and embedded in
paraffin. Among these 90 cases, 22 cases were available for
examination by RT–PCR analysis. These specimens were dissected
immediately into small pieces following gross dissection, quickly
transferred to liquid nitrogen, and then stored at  801C until
further use. The research protocol was approved by the ethics
committee of Tohoku University Graduate School of Medicine,
Sendai, Japan.
OVCAR3, Caov3, SKOV3, TOV112D, TOV21G, OV90 and ES2
(adenocarcinoma: OVCAR3, SKOV3; serous adenocarcinoma:
Caov3, OV90; clear cell adenocarcinoma: TOV21G, ES2; endo-
metrioid adenocarcinoma: TOV112D) cell lines were purchased
from American Type Culture Collection. JHOS2, JHOS3, HTOA,
OMC3 and JHOC5 (serous adenocarcinoma: JHOS2, JHOS3,
HTOA; mucinous adenocarcinoma: OMC3; clear cell adenocarci-
noma: JHOC5) cell lines were purchased from Riken cell bank
(Tsukuba, Japan). Cell lines were maintained in DMEM/F12
(Invitrogen, CA), supplemented with 10% foetal bovine serum
and 1% penicillin/streptomycin (Invitrogen, CA), and incubated in
5% CO2 at 371C.
Immunohistochemistry
Immunohistochemical analysis was performed using the strepta-
vidin–biotin amplification method using a Histofine Kit (Nichirei,
Tokyo, Japan), and have been previously described in detail
(Akahira JI et al, 2001, Akahira J et al, 2001). Oestrogen receptor-
binding fragment associated gene 9 antibody was a rabbit
polyclonal antibody against a GST-EBAG9 fusion protein
(Tsuchiya et al, 2001). The characterisation of this antibody was
confirmed by Western blotting (Suzuki et al, 2001). Monoclonal
antibody for ERa was purchased from Immunotech (Marseille,
France). For antigen retrieval, the slides were heated in an
autoclave at 1201C for 5min in citric acid buffer (2mM citric
acid and 9mM trisodium citrate dyhydrate, pH 6.0). The dilutions
of primary antibodies for EBAG9 and ERa were 1:200 and
1:2, respectively. The antigen–antibody complex was visualised
with 3,30-diaminobenzidine (DAB) solution (1mm DAB, 50mM
Tris-HCl buffer (pH 7.6) and 0.006% H2O2), and counterstained
with haematoxylin. The ER-positive breast carcinoma tissue
was used as a positive control for EBAG9 (Suzuki et al, 2001).
As negative controls, 0.01 M phosphate-buffered saline (PBS)
and normal mouse IgG were used in place of primary anti-
bodies. No specific immunoreactivity was detected in these
tissue sections.
Scoring of immunostaining
For statistical analyses of EBAG9 immunoreactivity, carcinomas
were classified independently by two of the authors (MA and JA)
into two groups: þ, positive carcinoma cells; and  ,n o
immunoreactivity. Cases with disconcordant results among the
observers were re-evaluated. For evaluation of ERa immuno-
reactivity, labeling index (LI) was obtained in carcinoma cells as
described by Sasano et al (1996). In brief, two of the authors (JA
and TM) independently evaluated at least 500 carcinoma cells
microsopically and the percentage of immunoreactivity was
determined. In the present study, interobserver differences were
less than 5%, and the mean of the two values was obtained.
Reverse transcription–PCR
Total RNA was isolated from tissues by phenol–chloroform
extraction using Isogen (Nippon Gene, Japan), and was treated
by DNase I (Roche, Germany). The RT–PCR kit (SUPERSCRIPT
Preamplification system, Invitrogen) was employed and cDNA
synthesis was carried out according to the instructions. cDNAs
were synthesised from 5mg of total RNA using random hexamer
and RT was carried out for 50min at 421C with SUPERSCRIPT II
reverse transcriptase. After an initial 1-min denaturation step at
941C, 35-cycle PCRs were carried out on a DNA thermal cycler
(PTC-200 DNA Engine, MJ Research, Inc., USA) under the
following conditions: 1-min denaturation at 941C, 1-min annealing
at 581C for EBAG9, 621C for ERa and 2-min extension at 721C.
Primers for PCR reactions were as follows: EBAG9: 50sense –
GCTACACAAGATTCTGCCT and 30 antisense – CTTCTTCATT
AGCCGTTGTG (680–892, 213bp); ERa:5 0 sense – AAGAGCTGCC
AGGCCTGCC and 30 antisense – TTGGCAGCTCTCATGTCTCC
(702–869, 168bp); b-actin: 50 sense – CCAACCGCGAGAAGAT
GAC and 30 antisense – GGAAGGAAGGCTGGAAGAGT (382–841,
459bp). In initial expreriments, following amplification, PCR
products were purified and subjected to direct sequencing to verify
amplification of the correct sequences (ABI prism 310 Genetic
Analyzer, Applied Biosystems, CA, USA). b-Actin primers were
utilised as positive controls. Negative controls without RNA and
without reverse transcriptase were also performed.
Immunoblotting
Cells were grown to 70% confluence in 10-cm plates and after
removal of culture medium with PBS, whole-cell protein was
extracted by conventional method. The protein concentration was
measured by Model 680 microplate reader (Biorad, USA) using
BradFord reagent (Biorad). In all, 20mg of protein of each sample
was mixed with an equal volume of 2  concentrated SDS–
polyacrylamide gel electrophoresis (SDS–PAGE) sample buffer,
boiled, and then electrophoresed on 7% ready-made gels contain-
ing SDS (Mini Protian II Western blotting system, Biorad).
Proteins were then transferred to nitrocellulose membrane
(Hybond PDVF, Biorad). The membranes were incubated in
blocking solution (PBS containing 5% nonfat milk and 0.05%
Tween-20), and then incubated in 1:200 dilution of EBAG9
antibody (1:2 for ERa and 1:1000 for Actin) in blocking solution
overnight at 41C. After incubation with HRP-rabelled anti-rabbit
IgG (Vector Laboratories, Inc., USA), the antigen–antibody
complex was visualised with ECL system (Amersham, Germany).
MCF-7 breast cancer cell line was used as a positive control
(Watanabe et al, 1998). Actin (Ab-1, Oncogene) was used as
internal positive controls.
Statistical analysis
Statistical analysis was performed using Stat View 5.0 (SAS
Institute Inc., NC, USA) software. The statistical significance
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using Mann–Whitney U-test, Kruskal–Wallis and Scheffe analy-
sis. The correlation between EBAG9 and ERa immunoreactivity
was also assessed using Mann–Whitney U-test. Univariate analysis
of prognostic significance for prognostic factors was performed
using a log-rank test, after each survival curve was obtained by the
Kaplan–Meier method. All patients who could be assessed were
included in the intention-to-treat analysis. A result was considered
significant when the P-value was less than 0.05.
RESULTS
Results of immunohistochemistry and their correlation with
clinicopathological parameters are summarised in Table 1. Im-
munoreactivity for EBAG9 was detected on the surface and in the
cytoplasm of epithelial ovarian cancer tissues. Oestrogen receptor
a immunoreactivity was confined exclusively to the nuclei of
tumour cells (Figure 1). The number of cases immunopositive for
EBAG9 was 46 out of 90 cases (51.1 %). The median LI for ERa was
12.8 % (0–85.2%). As shown in Table 1, EBAG9 expression was
significantly higher in serous histology (P¼0.0402) and advanced
disease (P¼0.0206). There was no significant relationship between
EBAG9 immunoreactivity and patient age, histological grade,
residual tumour or performance status. There was a highly
significant correlation between EBAG9 immunoreactivity and
ERa LI (Po0.0001).
Results of univariate analysis of prognostic significance for each
variable, with respect to survival, are summarised in Table 2.
Among the clinicopathological factors examined, those signifi-
cantly associated with overall survival were histology, grade, stage
and residual tumour. No significant relationship was detected
between EBAG9 immunoreactivity and overall survival (P¼0.689).
Relationships between EBAG9 immunoreactivity and EBAG9,
ERa mRNA in 22 cases are summarised in Table 3. Oestrogen
receptor-binding fragment associated gene 9 mRNA was positive
in 20 cases. In four cases, EBAG9 immunoreactivity was not
detected although its mRNA was present. In all of the cases that
Figure 1 Serial sections of positive and negative cases of immunohistochemistry for EBAG9 and ERa in epithelial ovarian carcinoma (A,B) a case of
serous adenocarcinoma, positive for both EBAG9 and ERa;( C,D) a case of clear-cell adenocarcinoma, negative for both EBAG9 and ERa). Immunoreactivity
for EBAG9 was detected on the surface, and in the cytoplasm of epithelial ovarian cancer tissues. ER-a immunoreactivity was confined exclusively to the
nuclei of tumour cells.
Table 1 Association between EBAG9 immunoreactivity and clinico-
pathological parameters in human ovarian cancer
EBAG9 immunoreactivity
+(n¼46) –(n¼44) P-value
Age (years) 52.871.8 49.571.5 NS
Histological type
Serous 27 14
Mucinous 7 9
Endometrioid 3 10
Clear cell 9 11 0.0402
Histological grade
Grade 1 15 16
Grade 2 11 15
Grade 3 12 6 NS
Stage
I,II 17 27
III,IV 29 17 0.0206
Residual tumour
o2cm 27 34
42cm 19 10 NS
PS
0,1 30 32
2,3,4 16 12 NS
ER LI 18.8 11.4 o0.0001
Performance status score: 0¼asymptomatic and fully active; 1¼symptomatic, fully
ambulatory, restricted in physically strenous activity; 2¼symptomatic, ambulatory,
capable of self-care, more than 50% of waking hours are spent out of bed;
3¼symptomatic, limited self-care, spends more than 50% of time in bed, but not
bedridden; 4¼completely disabled, no self-care, bedridden.
EBAG9 in ovarian cancer
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EBAG9 mRNA (Figure 2).
The result of immunoblotting is shown in Figure 3. Immuno-
reactive bands corresponding to EBAG9 and ERa were detected in
11 out of 12 and 10 out of 12 of ovarian cancer cell lines,
respectively. JHOS2, which was negative for EBAG9, was also
negative for ERa.
DISCUSSION
In the present study, EBAG9 immunoreactivity was detected in 46
out of 90 epithelial ovarian carcinomas (51.1%). The expression of
EBAG9 was significantly associated with advanced disease,
although it turned out not to be correlated with prognosis.
It is well recognised that human cancer tissues are infiltrated
with tumour-infiltrating lymphocytes (TIL) (Balch et al, 1990),
a phenomenon known to be a manifestation of the host
immune reaction to cancer cells (Rosenberg, 1996). Tumour-
infiltrating lymphocytes has been reported to be associated
with improved prognosis of some carcinomas, including lung
(DiPaola et al, 1977) and colon (Naito et al, 1998) carcinomas. In
ovarian tumour, the degree of lymphocyte infiltration was reported
to be associated with the patients’ survival rate, clinical stage,
grade and histological type (Ma and Gu, 1991). Nakashima et al
(1999) recently reported that activated CD3þ T lymphocytes
express a putative receptor for EBAG9/RCAS1. This receptor
expression was enhanced by activation of the lymphocytes, and
when these receptor-positive cells were cultured with EBAG9/
RCAS1 peptides, their growth was strongly suppressed, and they
were eventually led to cell death by apoptosis (Nakashima et al,
1999). In breast carcinoma, EBAG9 immunoreactivity was
inversely associated with the degree of intratumoral infiltration
of mononuclear cells or CD3þ T lymphocytes (Suzuki et al, 2001).
These results suggested that tumour cells might have evaded
immune surveillance by expressing EBAG9/RCAS1, which sup-
pressed clonal expansion and induced apoptosis of receptor-
positive immune cells. Although the precise mechanism of
immune evasion remains uncertain, the expression of EBAG9/
RCAS1 may be a factor related to the escape mechanism of cancer
cells from the host immune system.
Several authors reported that expression of RCAS1 was
associated with poor prognosis and/or advanced disease in
human cancer. Izumi et al (2001) reported that RCAS1 expression
was positive for 48 of 102 non-small-cell lung carcinoma
patients (47.1%) and was significantly correlated with advanced
stage, poor differentiation and poor prognosis. Ito et al (2003)
reported that RCAS1 overexpression was more frequently
observed in anaplastic carcinomas than well-differentiated carci-
noma in thyroid cancer. In pancreatic ductal adenocarcinoma,
RCAS1 expression was demonstrated in 77 of 80 cases (96%)
and was an independent prognostic factor (Hiraoka et al, 2002).
In gynaecological malignancies, Kaku et al (1999) reported
that patients with high RCAS1 expression showed significantly
worse overall survival than those with low expression in
adenocarcinoma of uterine cervix. In addition, Sonoda et al
(1998) reported that RCAS1 was not detected in the normal uterine
cervix or ovarian tissue, but strongly expressed in uterine
endometrial adenocarcinomas, ovarian adenocarcinomas (Sonoda
et al, 1996; Sonoda et al, 2000) and cervical squamous
cell carcinomas. Recently, Suzuki et al (2001) reported that
EBAG9 immunoreactivity was detected in 82 of 91 in breast
carcinoma (90.1%), although it was not associated with clinico-
pathological parameters. Others reported that EBAG9 gene
was consistently expressed in breast cancer cell line, and might
play a specific role in early stages of breast carcinogenesis
(Tsuneizumi et al, 2001). To our knowledge, this is the first report
that evaluated the relationships between EBAG9/RCAS1 and
clinicopathological parameters in epithelial ovarian cancer. Our
results, together with previous reports, suggest that ovarian
cancer that expresses EBAG9 may have invasive and progressive
characteristics.
There was a strong correlation between EBAG9 and ERa
immunoreactivity in ovarian cancer tissues (Po0.0001) and cell
lines in this study. Also, EBAG9 immunoreactivity was associated
with serous histology. Moreover, all of the cases that were positive
for ERa mRNA, were also positive for EBAG9 mRNA, suggesting
Table 2 Univariate analysis of overall survival
Variable P-value
EBAG9 immunoreactivity (+ vs  ) 0.689
Histological type 0.0177
Histological grade 0.0085
Stage o0.0001
Residual tumour o0.0001
Table 3 Association between EBAG9 immunoreactivity and RT–PCR
EBAG9 immunoreactivity
+–
EBAG9 mRNA + 16 4
  02
ERa mRNA + 9 2
  06
Figure 2 Representative results of RT–PCR for total RNA extracted
from epithelial ovarian carcinoma tissues. Bands of the correct size for
EBAG9 (213bp), ERa (168bp) and b-actin (459bp) were detected in each
histological subtype of ovarian cancer (1,2: serous; 3,4: mucinous; 5,6:
endometrioid; 7,8: clear cell). b-Actin was used as a positive control and
NC as a negative control. Note that all of the cases that were positive for
ERa mRNA were also positive for EBAG9 mRNA.
Figure 3 Results of immunoblotting of ovarian cancer cell lines are
shown. Actin was used as internal positive controls.
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ovarian epithelial carcinoma. Oestrogen receptor-binding frag-
ment associated gene 9 was isolated utilising a genomic-binding
site cloning method from a cDNA library of MCF-7 human breast
cancer cell (Watanabe et al, 1998), which expresses ERa and low
level of ERb (Vladusic et al, 2000). Transfection analyses have
demonstrated that the nucleotide sequences between  86 and  36
contains an ERE in the 50-promoter region of the EBAG9 gene
(Ikeda et al, 2000). mRNA levels of EBAG9 in MCF-7 cells are
significantly increased within 6h of oestrogen treatment, an effect
that is mediated by the binding of ERa to the ERE in the promoter
of the EBAG9 gene (Ikeda et al, 2000). On the other hand, Quinn
et al (1982) reported that serous tumours were more frequently
ER-positive than other types of cancers. Results from our present
study are consistent with these previous reports, and suggest that
EBAG9 is widely distributed in carcinoma cells of human epithelial
ovarian carcinoma tissues and cells, maybe especially in serous
histology, as a result of oestrogen actions through ER.
In conclusion, the wide distribution of EBAG9 and its relation to
advanced disease suggest that this protein may play important
roles in epithelial ovarian cancer. Further investigations are
required to clarify the precise functions of EBAG9 in epithelial
ovarian cancer.
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